Pfizer, Inc.(PFE) - Stock detail

Pfizer, Inc.

US
PFE
Pfizer Inc.(Listing date: 01/17/1944)

Pfizer Inc. was incorporated under the laws of Delaware on June 2, 1942. It is a research-based global biopharmaceutical company. Using science and global resources, the company brings therapies that extend and significantly improve people's lives through the discovery, development, manufacturing and distribution of healthcare products, including innovative medicines and vaccines. The company operates in both developed and emerging markets, committed to advancing health, prevention, treatment and cure for the world's most feared diseases of our time. It collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare services worldwide.

AI Value AnalystHold
Overall Rating4.3/10
Generated at:2026-06-03 17:40:07
Analysis based on 5 financial reports: 2025-12-31, 2025-03-30, 2024-12-31, 2024-06-30, 2024-03-31. Stock price data as of 2026-06-04. Data includes balance sheet, income statement, and valuation metrics for fundamental analysis. Analysis covers financial condition, profitability, and valuation aspects of Pfizer, Inc.
Overview

Pfizer, Inc. (PFE) is a financially stable global biopharmaceutical industry leader with strong gross margins and a robust product portfolio. The company is currently facing a post-pandemic revenue normalization phase, with recent year-over-year declines in sales and earnings. Valuation appears fair relative to its current growth profile, with no strong fundamental catalyst suggesting significant near-term upside.

Valuation
4/10
Profitability
4/10
Financial health
5/10
Operation Advice
  • Hold the stock at current levels.
  • The fundamental target price of $25.16 aligns closely with the current market price of $25.34, suggesting fair valuation.
  • Monitor the company's ability to return to sustainable revenue growth through its pipeline and new product launches.
  • Consider the stock for income-oriented investors given its likely dividend yield, but wait for clearer growth catalysts before adding to positions.

Valuation

P/E TTM
19.44
P/E LYR
18.50
P/B MRQ
1.62
P/S TTM
--
AI Analysis
  • The stock appears fairly valued based on recent earnings. The current price of $25.34 is near the lower end of the recent trading range and essentially at the calculated fundamental target price of $25.16. Valuation multiples (P/E ~19x, P/B ~1.6x, P/S ~2.3x) are within reasonable historical ranges for a large-cap pharmaceutical company with single-digit earnings growth prospects.
  • Current stock price is $25.34 as of 2026-06-04
  • Trailing twelve-month (TTM) P/E is 19.44 and forward P/E is 18.50
  • Price-to-book ratio is 1.62, indicating moderate premium to accounting book value
  • Price-to-sales ratio is 2.31, considered fair given high gross margins
  • Recent 60-day trading range is $25.24 to $28.64, with current price near the lower end
  • Fundamental valuation range based on P/E of 17x to 20x is approximately $23.12 to $27.20
  • Applying target P/E of 18.5x to TTM EPS of $1.36 gives fundamental target price of $25.16
  • Current market price of $25.34 is essentially at the target price, suggesting fair valuation
Valuation trend

Profitability

ROE TTM
8.90%
Net margin
12.48%
Gross margin
74.33%
Total revenue
62.58B
AI Analysis
  • Profitability has been under pressure post the peak of COVID-19 product cycle. Revenue and net income declined year-over-year in FY 2025, following a strong rebound in FY 2024. The company maintains very high gross margins but modest net margins and return metrics.
  • For FY 2025, revenue declined by 1.65% year-over-year to $62.58B
  • Net income declined by 3.24% to $7.77B in FY 2025
  • This follows a strong rebound in FY 2024 with revenue growth of 6.84% and net income growth of 279%
  • Company maintains very high gross margin of 74.33%, a strength of its business model
  • Net margin of 12.48% reflects significant costs associated with R&D, marketing, and administration
  • Return on Equity (ROE) is 8.90%, indicating acceptable but not exceptional returns
  • Return on Assets (ROA) is 3.69%, showing modest returns on total assets deployed
  • ROE is supported by financial leverage (debt)
Profitability
2024Q42025Q12025Q22025Q32025Q4
ROE TTM9.06%3.32%----8.90%
Earnings
2024Q42025Q12025Q22025Q32025Q4
Total revenue63.63B13.71B----62.58B

Financial health

Debt/Asset
58.31%
Current ratio
1.16
Quick ratio
0.87
Cash ratio
0.87
AI Analysis
  • Financial health shows a mixed picture with adequate but not strong liquidity metrics and moderate financial leverage. The balance sheet is characteristic of a mature pharmaceutical giant with significant operations and debt used for strategic purposes.
  • Current ratio of 1.16 indicates sufficient current assets to cover current liabilities, though margin is not substantial
  • Quick ratio of 0.87 is below 1, suggesting reliance on inventory to meet short-term obligations
  • Debt-to-asset ratio of 58.31% indicates moderate level of financial leverage
  • Leverage is manageable for a large, cash-generative pharmaceutical company but increases financial risk
  • Balance sheet is characteristic of a mature pharmaceutical giant with significant operations
  • Debt is used for strategic purposes such as acquisitions and R&D
  • Liquidity metrics are adequate but not strong
Leverage
2024Q42025Q12025Q22025Q32025Q4
Debt/Asset58.53%56.43%----58.31%
Liquidity
2024Q42025Q12025Q22025Q32025Q4
Current ratio1.171.26----1.16